Skip to main content
Clinical Trials/ISRCTN56034553
ISRCTN56034553CompletedNot Applicable

PREVEC Trial: Prevention of Reperfusion damage associated with percutaneous coronary angioplasty following acute myocardial infarction: a randomized double-blind placebo-controlled clinical trial

Scientific and Technological Development Fund (FONDECYT Fondo de Desarrollo Científico y Tecnológico) (Chile)0 sites132 target enrollmentStarted: January 28, 2013Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
132

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • 1. Subjects may be of either sex and must be at least 18 years old
  • 2. Subjects must have indication of primary percutaneous coronary angioplasty (PCA) as follows:
  • 2.1. Angina or equivalent at least 120 min duration
  • 2.2. Electrocardiogram (ECG) with STEMI that concerns more than 2 contiguous leads (>2mm)
  • 3. Presentation within 12 h of symptoms onset
  • 4. First myocardial infarction
  • 5. Subject must be able and willing to sign informed consent

Exclusion Criteria

  • 1. History of renal or hepatic insufficiency
  • 2. History of renal lithiasis (oxalates)
  • 3. History of heart failure (NYHA III, IV)
  • 4. Cardiogenic shock
  • 5. Any serious medical co-morbidity that determine life expectancy < 6 month
  • 6. Current participation in any other clinical investigation
  • 7. Pregnancy
  • 8. Glucose 6-phosphate dehydrogenase deficiency

Investigators

Sponsor
Scientific and Technological Development Fund (FONDECYT Fondo de Desarrollo Científico y Tecnológico) (Chile)

Similar Trials